Area of research
Aquatic Science · Infectious Diseases
Research interest
Research interests include Aquaculture Nutrition and Growth, SARS-CoV-2 and COVID-19 Research, Cancer-related molecular mechanisms research, and Cancer Immunotherapy and Biomarkers.
Carbonic anhydrase IX-targeted SMDCs for cancer precision treatment
From concept to application: Exploring the evolution and potential of DUBTAC technology.
A Multifunctional Prodrug with the DNA Damage Amplification Effect for Inducing Immunogenic Cell Death.
Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.
Rational Design of Imidazo[1,2-<i>a</i>]pyridine as an Effective TLR7 Antagonist for the Treatment of Psoriasis: Research Combined with In Silico Study.
Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma.
Targeting ADAR1 with a small molecule for the treatment of prostate cancer.
LIN28A-dependent lncRNA NEAT1 aggravates sepsis-induced acute respiratory distress syndrome through destabilizing ACE2 mRNA by RNA methylation
Antiviral signaling of a type III CRISPR-associated deaminase.
Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction.
ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
Comparative analysis of the non-volatile flavor of mud crab (Scylla paramamosain) cultured in sea water and coastal low saline-alkali water
Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents.
Targeting Protein Tyrosine Phosphatase Nonreceptor Type 2 with a Novel Inhibitor for the Treatment of Melanoma.
Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.
ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.
Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer.
Discovery of a Novel and Potent <i>MET</i> Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLC.
Development of Novel PTPN2/1 Inhibitors for the Treatment of Melanoma.
TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy.
Preclinical Efficacy of TSL2109 in Prostate Cancer Treatment and Overcoming Enzalutamide Resistance.
Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate Cancer.
Call for Papers: Pharmaceutical Innovation and Global Health: Breakthroughs and Future─Celebrating the 90th Anniversary of China Pharmaceutical University
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors.
Based on metabolomics analysis: metabolic mechanism of intestinal tract of Scylla paramamosain under low-salt saline-alkali water aquaculture environment
Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment
Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment.
Effects of aquatic Ca2+ and Mg2+ on the antioxidant, immune, osmotic regulation, molting, and metabolic abilities of Scylla paramamosain